Hester Biosciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Hester Biosciences Ltd reported a 6.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 5.6%.
• Its expenses for the quarter were down by 2.2% QoQ and 11.8% YoY.
• The net profit decreased 17.1% QoQ and increased 70.8% YoY.
• The earnings per share (EPS) of Hester Biosciences Ltd stood at 16.85 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Hester Biosciences Ltd is a leading player in the animal healthcare industry, primarily involved in the production of vaccines and health products for poultry and large animals. Established in India, the company is recognized for its focus on quality and innovation in vaccine production. While specific recent developments are not provided in the data, Hester Biosciences is known for its strategic expansions and collaborations in the vaccine sector. As a biosciences company, Hester operates in a niche market that requires constant research and regulatory compliance, which impacts its operational strategies and financial performance.

Revenue

During the second quarter of fiscal year 2026 (Q2FY26), Hester Biosciences Ltd reported a total income of ₹80.70 crores. This marks a decrease of 6.6% from the first quarter of the same fiscal year (Q1FY26), where the total income was ₹86.42 crores. Compared to the same quarter in the previous fiscal year (Q2FY25), the total income decreased by 5.6% from ₹85.53 crores. These figures highlight the revenue trends on a sequential and annual basis, reflecting the company’s efforts in managing its income streams amid market dynamics.

Profitability

The profitability metrics for Hester Biosciences Ltd in Q2FY26 indicate a profit before tax (PBT) of ₹14.88 crores. This represents a decline of 22.3% from the previous quarter's PBT of ₹19.14 crores. However, when compared to Q2FY25, where the PBT was ₹10.91 crores, there is a significant increase of 36.4%. The profit after tax (PAT) for Q2FY26 stands at ₹14.33 crores, showing a reduction of 17.1% from Q1FY26 but a substantial increase of 70.8% from the same quarter last year. The earnings per share (EPS) also reflect similar trends, with a sequential decline of 17.1% and a yearly increase of 70.9%.

Operating Metrics

The total expenses for Hester Biosciences Ltd in Q2FY26 amounted to ₹65.81 crores, demonstrating a 2.2% decrease from Q1FY26's expenses of ₹67.28 crores. Compared to Q2FY25, there is a notable year-on-year decrease of 11.8% from ₹74.62 crores. The tax expenses in Q2FY26 were ₹2.70 crores, showing a decrease of 6.6% from the previous quarter and a reduction of 22.4% from the same quarter last year. These metrics provide insights into the company’s operational efficiency and cost management during the analyzed periods.